BondTrue

Executive Summary

BondTrue is a private, early-stage medical device company founded in 2020 and headquartered in San Francisco, CA. The company specializes in surgical incision and wound closure technology, leveraging engineering and artificial intelligence/machine learning to innovate in the surgical tools sector. BondTrue is a portfolio company of TEDCO and has received grant funding from the National Science Foundation and the state of Maryland, underscoring its potential in advancing wound closure solutions. As an early-stage venture, BondTrue operates in a competitive but high-demand market, with its AI/ML integration offering a differentiated approach to surgical devices. The company's focus on improving surgical outcomes and reducing recovery times positions it well for growth, though it remains pre-revenue and privately held, with limited public information on its financials or development pipeline. The executive summary highlights BondTrue's strategic grants and technological focus, which could drive near-term milestones and investor interest.

Upcoming Catalysts (preview)

• Q3 2026Completion of preclinical or early clinical trials for lead wound closure device60% success
• Q4 2026New grant or commercialization partnership with a major medical center50% success
• Q1 2027Series A or seed extension funding round55% success